Pulmonx Corp LUNG.OQ LUNG.O is expected to show a rise in quarterly revenue when it reports results on April 30 for the period ending March 31 2025
The Redwood City California-based company is expected to report a 16.9% increase in revenue to $22.034 million from $18.85 million a year ago, according to the mean estimate from 7 analysts, based on LSEG data.
LSEG's mean analyst estimate for Pulmonx Corp is for a loss of 40 cents per share.
The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 5 "strong buy" or "buy," 2 "hold" and no "sell" or "strong sell."
The mean earnings estimate of analysts was unchanged in the last three months.
Wall Street's median 12-month price target for Pulmonx Corp is $12.00, above its last closing price of $5.20.
Previous quarterly performance (using preferred earnings measure in US dollars).
QUARTER ENDING
STARMINESMARTESTIMATE®
LSEG IBES ESTIMATE
ACTUAL
BEAT, MET, MISSED
SURPRISE %
Dec. 31 2024
-0.44
-0.45
-0.33
Beat
26.3
Sep. 30 2024
-0.45
-0.45
-0.36
Beat
19.7
Jun. 30 2024
-0.42
-0.43
-0.35
Beat
17.7
Mar. 31 2024
-0.45
-0.46
-0.36
Beat
22
Dec. 31 2023
-0.38
-0.41
-0.36
Beat
11.6
Sep. 30 2023
-0.42
-0.43
-0.39
Beat
8.8
Jun. 30 2023
-0.44
-0.44
-0.43
Beat
1.6
Mar. 31 2023
-0.44
-0.44
-0.42
Beat
4.5
This summary was machine generated April 28 at 21:04 GMT. All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)